NCT04479280

Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.

Evaluation of the Role of Sonoclot Signature in Assessment of Coagulopathy in Critically Ill COVID 19 Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 70 (actual)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world . Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation

Conditions

• Coagulation Disorder

Interventions

Type	Name	Description
DEVICE	Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA	studying coagulation disorders in COVID19 critically ill patients

Timeline

• Start date: 2020-07-20
• Primary completion: 2020-08-16
• Completion: 2020-08-16
• First posted: 2020-07-21
• Last updated: 2020-09-09

Locations

1 site across 1 country: Egypt

Regulatory

• FDA-regulated device study